$2M grant awarded to Histogen to study knee cartilage regeneration

Alan Condon -   Print  |
Listen

Regenerative medicine company Histogen has received a $2 million grant to help fund a clinical trial for knee cartilage regeneration.

Three things to know:

1. The funding was provided by the Peer Reviewed Orthopedic Research Program of the U.S. Department of Defense.

2. The phase 1/2 clinical trial will study HST-003, a biologic product that regenerates tissue, in a microfracture procedure in 15 patients with focal cartilage defects in the knee.

3. OasisMD in San Diego, The Steadman Clinic in Vail, Colo., and Walter Reed Medical Center in Bethesda, Md., will serve as clinical sites for the trial.

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers